Dihydroartemisinin is named as an intervention in 5 current clinical trials in our China register. 3 are recruiting patients now. The most common phase is Phase 2. The sponsor with the most trials is Shanghai Zhongshan Hospital (2). The most-studied condition is Discoid Lupus Erythematosus.
| Study | Phase | Status | Lead sponsor | Registers |
|---|---|---|---|---|
|
Efficacy of Dihydroartemisinin for Treating Acne Vulgaris
NCT07007078 · ClinicalTrials.gov ↗ · Acne Vulgaris
|
Phase EARLY_PHASE1 | Recruiting | Shanghai Zhongshan Hospital | China |
|
Dihydroartemisinin for the Treatment of Polycystic Ovary Syndrome
NCT06842524 · ClinicalTrials.gov ↗ · Polycystic Ovary Syndrome (PCOS)
|
Phase 2 | Recruiting | Shanghai Zhongshan Hospital | China |
|
Dihydroartemisinin for MAFLD
NCT07679542 · ClinicalTrials.gov ↗ · MAFLD
|
Phase 1/2 | Recruiting | The First Affiliated Hospital with Nanjing Medical University | China |
|
A Multicentre, Randomised, Double-blind, Positive-control Clinical Trial Evaluating Dihydroartemisinin Tablets for the Treatment of Discoid Lupus Erythematosus
NCT07557927 · Discoid Lupus Erythematosus
|
Phase 2 | Not yet open | Kunming Pharmaceuticals, Inc. | China |
|
CapeOx Combined With Anti-PD1 Antibody Plus Dihydroartemisinin as Neoadjuvant or Conversion Therapy for Microsatellite Stable Locally Advanced and Metastatic Colorectal Cancer
NCT07801352 · ClinicalTrials.gov ↗ · Locally Advanced Colorectal Cancer, Metastatic Colorectal Cancer
|
Phase 2 | Active, closed | Shanghai Changzheng Hospital | China |
Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Trial titles and statuses are copied from the registry as published.
| Lead sponsor | Trials |
|---|---|
| Shanghai Zhongshan Hospital | 2 |
| Kunming Pharmaceuticals, Inc. | 1 |
| The First Affiliated Hospital with Nanjing Medical University | 1 |
| Shanghai Changzheng Hospital | 1 |
| Register | Trials | Recruiting |
|---|---|---|
| Clinical trials in China | 5 | 3 |
A trial with sites in more than one country appears in each of those registers.
5 current trials in our China register name Dihydroartemisinin as a drug or biological intervention, as of the registry sync on 25 September 2026. Completed and withdrawn studies are not counted.
Yes. 3 of the 5 trials are recruiting: 3 with sites in China. Eligibility and site contacts are on each trial's record. Only the study team can confirm whether a patient is eligible.
Shanghai Zhongshan Hospital (2), Kunming Pharmaceuticals, Inc (1), The First Affiliated Hospital with Nanjing Medical University (1) and Shanghai Changzheng Hospital (1). The number in brackets is how many trials each organisation leads.
Every trial, status, phase and sponsor on this page is copied from public ClinicalTrials.gov records by a daily sync. Nothing here describes how Dihydroartemisinin works or whether it is effective, and it is not medical advice.
Everything on this page is copied from public ClinicalTrials.gov registry records — it is not written from memory, and nothing here describes how Dihydroartemisinin works or whether it is effective. Each trial links to its own record so you can check it yourself.
This page is built automatically: a daily sync job reads the registry records behind our country trial registers, collects every trial that lists Dihydroartemisinin (or a registered synonym) as a drug or biological intervention, and tabulates the registry fields directly. Placebos and generic comparators are excluded. There is no AI drafting and no per-compound editorial pass, and the page has not been clinically reviewed. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The ClinicalTrials.gov data on this page was last retrieved on 25 Sep 2026.